Benigne und präinvasive Läsion der Brust

Zahlreiche Läsionen in der Brust sind Differenzialdiagnosen gutartiger Herd- und Tastbefunde sowie bildgebender Zufallsbefunde. Sie können benigne oder prämaligne sein, oder es handelt sich um Vorläufer- oder gar Indikatorläsionen eines Brustkrebses. Entsprechend ihrem heterogenen Erscheinungsbild ist auch die Therapie nicht einheitlich und von Begleitfaktoren abhängig.

Schlüsselwörter

Gutartige Veränderungen der Brust - unklares biologisches Potenzial - B3-Läsionen der Brust - Vorläuferläsionen der Brust - Indikatorläsionen der Brust

• Literatur

• 1 Griesbaum R, Peters F. Onkologie. Fibroadenom: Diagnostik und Therapie. Geburtsh Frauenheilk 2008; 68: 941-944
• 2 Dupont WD, Page DL, Parl FF. et al. Long-term risk of breast cancer in women with fibroadenoma. Engl J Med 1994; 331: 10-15
• 3 McDivitt RW, Stevens JA, Lee NC. et al. Histologic types of benign breast disease and the risk for breast cancer. Cancer 1992; 69: 1408-1414
• 4 Aktuelle Empfehlungen der AGO Kommission Mamma 2019, aktualisiert 18.3.2019. Im Internet: http://www.ago-online.de/de/infothek-fuer-aerzte/leitlinienempfehlungen/mamma/ Stand: 12.04.2019
• 5 Bernstein L, Deapen D, Ross RK. The descriptive epidemiology of malignant cystosarcoma phyllodes tumors of the breast. Cancer 1993; 71: 3020-3024
• 6 MacDonald OK, Lee CM, Tward JD. et al. Malignant phyllodes tumor of the female breast: association of primary therapy with cause-specific survival from the Surveillance, Epidemiology, and End Results (SEER) program. Cancer 2006; 107: 2127-2133
• 7 Norris HJ, Taylor HB. Relationship of histologic features to behavior of cystosarcoma phyllodes. Analysis of ninety-four cases. Cancer 1967; 20: 2090-2099
• 8 Golatta M, Harcos A, Junkermann H, Heil J. Benigne Befunde in der Mammasonografie. In: Sohn C, Holzgreve W. Hrsg. Ultraschall in Gynäkologie und Geburtshilfe. Stuttgart: Thieme; 2013: 728-736
• 9 Bellocq JP, Magro G. Fibroepithelial Tumours. In: Tavassoli FA, Devilee P, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Breast and female genital Organs. Lyon: IARC Press; 2003: 99-103
• 10 Wahner-Roedler DL, Sebo TJ, Gisvold JJ. Hamartomas of the breast: clinical, radiologic and pathologic manifestations. Breast J 2001; 7: 101-105
• 11 Mester J, Simmons RM, Vazquez MF. et al. In situ and infiltrating ductal carcinoma arising in a breast hamartoma. Am J Roentgenol 2000; 175: 64-66
• 12 Universitätsklinikum Bonn. Humangenetik. Im Internet: http://www.humangenetics.uni-bonn.de/de/beratung/erbliche-tumorerkrankungen/krankheitsbilder/cowden-syndrom Stand: 12.04.2019
• 13 Wen X, Cheng W. Nonmalignant breast papillary lesions at core-needle biopsy: a meta-analysis of underestimation and influencing factors. Ann Surg Oncol 2013; 20: 94-101
• 14 S3-Leitlinie Mammakarzinom Version 4.1. 2018. Im Internet: http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/ Stand: 12.04.2019
• 15 Calhoun BC, Collin LC. Recommendations for excision following core needle biopsy of the breast: a contemporary evaluation of the literature. Histopathology 2016; 68: 138-151
• 16 Farshid G, Buckley E. Meta-analysis of upgrade rates in 3163 radial scars excised after needle core biopsy diagnosis. Breast Cancer Res Treat 2018; 174: 165-177
• 17 Bunting DM, Steel JR, Holgate CS. et al. Long term follow-up and risk of breast cancer after a radial scar orcomplex sclerosinglesion has been identified in a benign open breast biopsy. Eur J Surg Oncol 2011; 37: 709-713
• 18 Boulos FI, Dupont WD, Simpson JF. et al. Histologic associations and long-term cancer risk in columnar cell lesions of the breast: a retrospective cohort and a nested case-control study. Cancer 2008; 113: 2415-2421
• 19 Calhoun BC, Sobel A, White RL. et al. Management of flat epithelial atypia on breast core biopsy may be individualized based on correlation with imaging studies. Modern Pathology 2015; 28: 670-676
• 20 Said SM, Visscher DW, Nassar A. et al. Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Cancer 2015; 121: 1548-1555
• 21 Andersen JA. Lobular carcinoma in situ. A long-term follow-up in 52 cases. Acta Pathol Microbiol Scand A 1974; 82: 519-533
• 22 Ottesen GL, Graversen HP, Blichert-Toft M. et al. Lobular carcinoma in situ of the female breast. Short-term results of a prospective nationwide study. The Danish Breast Cancer Cooperative Group. Am J Surg Pathol 1993; 17: 14-21
• 23 RKI. Krebs in Deutschland 2011/2012. 2015 2015. Im Internet: http://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/kid_2015/krebs_in_deutschland_2015.pdf Stand: 12.04.2019
• 24 Cuzick J, Sestak I, Cawthorn S. et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 2015; 16: 67-75
• 25 Cuzick J, Sestak I, Pinder SE. et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results form the UK/ANZ DCIS trial. Lancet Oncol 2010; 12: 21-29
• 26 Donker M, Litière S, Werutsky G. et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma In Situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 2013; 31: 4054-4059
• 27 Wapnir Il. Dignam JJ, Fisher B. et al. Long term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B17 and B24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011; 103: 478-488
• 28 Warnberg F, Garmo H, Emdin S. et al. Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial. J Clin Oncol 2014; 32: 3613-3618
• 29 Subhedar P, Olcese C, Patil S. et al. Decreasing recurrence rates for ductal carcinoma in situ: analysis of 2996 women treated with breast-conserving surgery over 30 years. Ann Surg Oncol 2015; 22: 3273-3281
• 30 Kerlikowske K, Molinaro AM, Gauthier ML. Biomarkers expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 2010; 102: 627-637
• 31 Levine M. Steering Committee on Clinical Practice Guidelines for the Care and treatment of Breast Cancer. Management of ductal carcinoma in situ (summary of the 2001 update). Canadian Med Assoc J 2001; 165: 912-913
• 32 Page DL, Dupont WD, Rogers LW. et al. Continued local recurrence of carcinoma 15-25 years of diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 1995; 76: 1197-2000
• 33 Narod SA, Iqbal J, Giannakeas V. et al. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol 2015; 1: 888-896
• 34 Goodwin A, Parker S, Ghersi D. et al. Post-operative radiotherapy for ductal carcinoma in situ of the breast. Cochrane Database Syst Rev 2013; (11) CD000563
• 35 Staley H, McCallum I, Bruce J. Postoperative tamoxifen for ductal carcinoma in situ: Cochrane systematic review and meta-analysis. Breast 2014; 23: 546-551 doi:10.1016/j.breast.2014.06.015
• 36 Guerrieri-Gonzaga A, Lazzeroni M, Botteri E. et al. Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. Ann Oncol 2013; 24: 1859-1866